Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
1564 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Colorectal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Colorectal Cancer - Pipeline Review, H1 2016', provides an overview of the Colorectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer - The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects - The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Colorectal Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 8 Colorectal Cancer Overview 9 Therapeutics Development 10 Colorectal Cancer - Therapeutics under Development by Companies 12 Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 32 Colorectal Cancer - Pipeline Products Glance 34 Colorectal Cancer - Products under Development by Companies 38 Colorectal Cancer - Products under Investigation by Universities/Institutes 65 Colorectal Cancer - Companies Involved in Therapeutics Development 68 Colorectal Cancer - Therapeutics Assessment 295 Drug Profiles 339 Colorectal Cancer - Dormant Projects 1462 Colorectal Cancer - Discontinued Products 1489 Colorectal Cancer - Product Development Milestones 1496 Appendix 1513
List of Tables
Number of Products under Development for Colorectal Cancer, H1 2016 60 Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2016 61 Number of Products under Development by Companies, H1 2016 63 Number of Products under Development by Companies, H1 2016 (Contd..1) 64 Number of Products under Development by Companies, H1 2016 (Contd..2) 65 Number of Products under Development by Companies, H1 2016 (Contd..3) 66 Number of Products under Development by Companies, H1 2016 (Contd..4) 67 Number of Products under Development by Companies, H1 2016 (Contd..5) 68 Number of Products under Development by Companies, H1 2016 (Contd..6) 69 Number of Products under Development by Companies, H1 2016 (Contd..7) 70 Number of Products under Development by Companies, H1 2016 (Contd..8) 71 Number of Products under Development by Companies, H1 2016 (Contd..9) 72 Number of Products under Development by Companies, H1 2016 (Contd..10) 73 Number of Products under Development by Companies, H1 2016 (Contd..11) 74 Number of Products under Development by Companies, H1 2016 (Contd..12) 75 Number of Products under Development by Companies, H1 2016 (Contd..13) 76 Number of Products under Development by Companies, H1 2016 (Contd..14) 77 Number of Products under Development by Companies, H1 2016 (Contd..15) 78 Number of Products under Development by Companies, H1 2016 (Contd..16) 79 Number of Products under Development by Companies, H1 2016 (Contd..17) 80 Number of Products under Development by Companies, H1 2016 (Contd..18) 81 Number of Products under Investigation by Universities/Institutes, H1 2016 82 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 83 Comparative Analysis by Late Stage Development, H1 2016 84 Comparative Analysis by Clinical Stage Development, H1 2016 85 Comparative Analysis by Early Stage Development, H1 2016 86 Comparative Analysis by Unknown Stage Development, H1 2016 87 Products under Development by Companies, H1 2016 88 Products under Development by Companies, H1 2016 (Contd..1) 89 Products under Development by Companies, H1 2016 (Contd..2) 90 Products under Development by Companies, H1 2016 (Contd..3) 91 Products under Development by Companies, H1 2016 (Contd..4) 92 Products under Development by Companies, H1 2016 (Contd..5) 93 Products under Development by Companies, H1 2016 (Contd..6) 94 Products under Development by Companies, H1 2016 (Contd..7) 95 Products under Development by Companies, H1 2016 (Contd..8) 96 Products under Development by Companies, H1 2016 (Contd..9) 97 Products under Development by Companies, H1 2016 (Contd..10) 98 Products under Development by Companies, H1 2016 (Contd..11) 99 Products under Development by Companies, H1 2016 (Contd..12) 100 Products under Development by Companies, H1 2016 (Contd..13) 101 Products under Development by Companies, H1 2016 (Contd..14) 102 Products under Development by Companies, H1 2016 (Contd..15) 103 Products under Development by Companies, H1 2016 (Contd..16) 104 Products under Development by Companies, H1 2016 (Contd..17) 105 Products under Development by Companies, H1 2016 (Contd..18) 106 Products under Development by Companies, H1 2016 (Contd..19) 107 Products under Development by Companies, H1 2016 (Contd..20) 108 Products under Development by Companies, H1 2016 (Contd..21) 109 Products under Development by Companies, H1 2016 (Contd..22) 110 Products under Development by Companies, H1 2016 (Contd..23) 111 Products under Development by Companies, H1 2016 (Contd..24) 112 Products under Development by Companies, H1 2016 (Contd..25) 113 Products under Development by Companies, H1 2016 (Contd..26) 114 Products under Investigation by Universities/Institutes, H1 2016 115 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 116 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 117 Colorectal Cancer - Pipeline by 2cureX ApS, H1 2016 118 Colorectal Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 119 Colorectal Cancer - Pipeline by 4SC AG, H1 2016 120 Colorectal Cancer - Pipeline by AB Science SA, H1 2016 121 Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016 122 Colorectal Cancer - Pipeline by AbGenomics International, Inc., H1 2016 123 Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 124 Colorectal Cancer - Pipeline by Adamed Sp. z o.o., H1 2016 125 Colorectal Cancer - Pipeline by Advaxis, Inc., H1 2016 126 Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 127 Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016 128 Colorectal Cancer - Pipeline by Allinky Biopharma, H1 2016 129 Colorectal Cancer - Pipeline by Amal Therapeutics SA, H1 2016 130 Colorectal Cancer - Pipeline by Amgen Inc., H1 2016 131 Colorectal Cancer - Pipeline by Antibe Therapeutics, Inc., H1 2016 132 Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016 133 Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016 134 Colorectal Cancer - Pipeline by Aphios Corporation, H1 2016 135 Colorectal Cancer - Pipeline by Aposense Ltd., H1 2016 136 Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 137 Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016 138 Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016 139 Colorectal Cancer - Pipeline by Astellas Pharma Inc., H1 2016 140 Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 141 Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016 142 Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 143 Colorectal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 144 Colorectal Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016 145 Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 146 Colorectal Cancer - Pipeline by Bayer AG, H1 2016 147 Colorectal Cancer - Pipeline by BeiGene, Ltd., H1 2016 148 Colorectal Cancer - Pipeline by Biocon Limited, H1 2016 149 Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016 150 Colorectal Cancer - Pipeline by Bionovis SA, H1 2016 151 Colorectal Cancer - Pipeline by Biotecnol, Inc., H1 2016 152 Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 153 Colorectal Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 154 Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 155 Colorectal Cancer - Pipeline by Burzynski Research Institute, Inc., H1 2016 156 Colorectal Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016 157 Colorectal Cancer - Pipeline by Carna Biosciences, Inc., H1 2016 158 Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2016 159 Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016 160 Colorectal Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 161 Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016 162 Colorectal Cancer - Pipeline by Cellceutix Corporation, H1 2016 163 Colorectal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 164 Colorectal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 165 Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016 166 Colorectal Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016 167 Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 168 Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016 169 Colorectal Cancer - Pipeline by Cleave Biosciences, H1 2016 170 Colorectal Cancer - Pipeline by Cleveland BioLabs, Inc., H1 2016 171 Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016 172 Colorectal Cancer - Pipeline by Coare Biotechnology, Inc., H1 2016 173 Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 174 Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 175 Colorectal Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 176 Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 177 Colorectal Cancer - Pipeline by CritiTech, Inc., H1 2016 178 Colorectal Cancer - Pipeline by CrystalGenomics, Inc., H1 2016 179 Colorectal Cancer - Pipeline by Cytune Pharma SAS, H1 2016 180 Colorectal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 181 Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016 182 Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 183 Colorectal Cancer - Pipeline by Delcath Systems, Inc., H1 2016 184 Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 185 Colorectal Cancer - Pipeline by Digna Biotech, S.L., H1 2016 186 Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 187 Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 188 Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016 189 Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016 190
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
